Genix Pharmaceuticals Corporation
GENX.V
TSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 800.00 | 2.90K | 3.00K | 2.90K | 4.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 800.00 | 2.90K | 3.00K | 2.90K | 4.20K |
| Cost of Revenue | 134.40K | 135.40K | 135.40K | 1.30K | 1.30K |
| Gross Profit | -133.50K | -132.30K | -132.30K | 1.70K | 2.90K |
| SG&A Expenses | 118.00K | 125.40K | 133.80K | 168.10K | 156.50K |
| Depreciation & Amortization | 800.00 | 800.00 | 800.00 | 100.70K | 202.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 253.20K | 261.60K | 270.10K | 270.20K | 360.30K |
| Operating Income | -252.40K | -258.60K | -267.00K | -267.20K | -356.00K |
| Income Before Tax | -59.30K | -86.00K | -54.20K | -2.94M | -3.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.06 | -0.09 | -0.05 | -2.94 | -3.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.30K | -86.00K | -54.20K | -2.94M | -3.01M |
| EBIT | -252.40K | -258.60K | -267.00K | -267.20K | -356.00K |
| EBITDA | -52.90K | -59.10K | -67.50K | -68.40K | -154.40K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.05 | -0.05 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.05 | -0.05 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 236.90M | 236.90M | 236.90M | 236.90M | 236.90M |
| Average Diluted Shares Outstanding | 236.90M | 236.90M | 236.90M | 236.90M | 236.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |